New Delhi, July 18, 2016
Some of the key highlights are:
– The IPM grew at 13% as of on MAT June 2016
– The IPM was valued at Rs. 107,019 crores and the retail sector was valued at Rs.89,784 crores as of MAT June 2016
– All therapies have seen a dip since February 2016. However, GI (Gastro Intestinal) has shown a growth in June 2016 over May 2016
– Respiratory is the largest affected market by the ban with 71% of the value of banned drugs being contributed by 6 molecule combinations. However, Dextromethorphan + Chlorpheniramine combinations and Bromhexine combinations have shown improved growth in June 2016
Corporate Comm India(CCI Newswire)
New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…